Figure 3. Overall Survival in Patients With MSI-H Tumors and PD-L1 CPS of 1 or Greater.
Kaplan-Meier estimates of overall survival in patients with microsatellite instability–high (MSI-H) tumors in the programmed cell death ligand 1 (PD-L1) combined positive score (CPS) of 1 or greater population for pembrolizumab (A) and pembrolizumab plus chemotherapy (B) vs chemotherapy. Analysis of overall survival in patients with MSI-H tumors was not adjusted for multiplicity.